NCT00424749View on ClinicalTrials.gov

Rituxan in Churg Strauss Syndrome With Renal Involvement

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Churg-Strauss Syndrome
Interventions
DRUG

Rituximab

Patients received 4 weekly doses of rituximab 375 mg/m\^2.

DRUG

Prednisone

Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Collaborators (2)

Genentech, Inc.
Biogen
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Biogen

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Fernando Fervenza

OTHER

NCT00424749 - Rituxan in Churg Strauss Syndrome With Renal Involvement | Biotech Hunter | Biotech Hunter